Risk-adjustment system for the Medicare capitated ESRD program
Related Experiment Videos
Jesse M Levy1, John Robst, Melvin J Ingber
1Centers for Medicare & Medicaid Services, Baltimore, MD 21244-1850, USA. jesse.levy@cms.hhs.gov
Abstract:
Medicare is the principal payer for medical services for those in the U.S. population suffering from end-stage renal disease (ESRD). By law, beneficiaries diagnosed with ESRD may not subsequently enroll in Medicare Advantage (MA) plans, however, the potential benefits of managed care for this population have stimulated interest in changing the law and developing demonstration plans. We describe a new risk-adjustment system developed for Medicare to pay for ESRD beneficiaries in managed care plans. The model improves on current payment methodology by adjusting payments for treatment status and comorbidities.
Related Concept Videos
Renal Failure: Dose Adjustments
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Drug Dosing in Renal Diseases: Estimation of Glomerular Filtration Rate Based on Serum Creatinine Concentration
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Continuous Renal Replacement Therapy
Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant
Extracorporeal Removal of Drugs: Continuous Renal Replacement Therapy